Over the last decade, the European medical cannabis landscape has seen a significant surge of new products entering the market, providing patients, especially in the UK and Germany, with a greater variety than ever before.
In the early years of the European medical cannabis market (2017-2020), medical cannabis products in Europe predominantly stemmed from the Netherlands through products provided by Bedrocan; however, in recent years, Canada has emerged as the leading supplier to European markets.
However, as more European markets expand their medical cannabis frameworks, demand is growing rapidly for an increased variety and volume of products sourced through global and domestic supply chains. As these supply chains develop, product availability has expanded, and European patients now have unprecedented levels of choice.
The extent to which individual markets are able to offer a variety of products, price points, and formats is driven by a multitude of factors. These include the specific classification of medical cannabis, the product authorisation process, the number of patients/demand, regulations on imports, patient access and the level of competition.
The surge of medical cannabis product availability in Europe is most prominently seen in the German and UK markets. Both of these markets can be defined as free markets within the European medical cannabis industry due to their relatively low barriers of entry for companies and high patient demand.
Upcoming: Prohibition Partners, The European Cannabis Report: 10th Edition – Pre-Order Now
When assessing the number of products available to patients in the UK and Germany, it is clear that German patients have a larger selection of medical cannabis products, totalling 1,104 products, compared to the UK, totalling 399 medical cannabis products.
However, in terms of product format variety, the UK patients have more choices, as edibles and a broader range of vape products are available. The disparity between the two countries in terms of the number of products and product format variety is driven by several factors, including the patient size, the level of competition and the classification of medical cannabis.
Germany is by far the largest medical cannabis market in Europe in terms of patient size as well as product availability. In 2024 alone, the country imported over 72 tonnes of medical cannabis, which was fueled by 4th quarter imports following the implementation of the CanG and MedCanG.
The newly established cannabis framework in the country removed cannabis from Germany’s list of narcotics, as well as eased the trade, dispensation and prescribing of medical cannabis. This sparked a significant rise in private-pay patients, and thus the demand for imported products.
Although there is an extensive variety of flowers and extracts available on the German market, there are no edibles and only one vape product available. This is due to the fact that medical cannabis in Germany is sold as a magistral product and not as a prepackaged finished good; thus, the last production step, checking product quality and dose packaging, occurs in the pharmacies.
However, some pharmacies provide services such as creating capsules and formulations from extracts. Additionally, the one vape product on the market is assembled by the pharmacy itself.
Upcoming: Prohibition Partners, The European Cannabis Report: 10th Edition – Pre-Order Now
Due to the high level of competition and the wide range of medical cannabis flowers available in Germany, there is a large spread in average prices, ranging from roughly €4 – €17 per gram. The prices for medical cannabis flower have seen a significant fall throughout the years, as back in 2018 the average price was roughly €20 – €24 per gram; however, following the rise of patients, the adoption of the MedCanG and increased competition between suppliers, the most common price of medical cannabis flower is around €8 – €9 per gram.
It must also be noted that, as there is a considerable number of low-cost options available on the medical cannabis market, patients who historically purchased cannabis illicitly for their treatment no longer need to do so, as prices are lower than those found on the illicit market.
For more information on Germany’s medical cannabis prices, visit BofC X Mary Jane 2025, where experts will discuss Germany’s adult-use market on the 19th June 2025.
Compared to Germany, the UK’s medical cannabis market is significantly smaller due to its stringent import and prescription requirements and the fact that the market is focused entirely on private-pay patients.
Medical cannabis in the UK is classified as an unlicensed special medicine; thus, importers are bound to strict licence requirements to import specials, only doctors with an FP10 controlled prescription pad on the GMC Specialist Register are allowed to prescribe medical cannabis and before each initial prescription a multidisciplinary peer group must discuss to decide if medical cannabis treatment is suitable for the patient.
In the UK, medical cannabis is sold as a finished product in pharmacies, thus, there is a larger variety in formats in the UK compared to Germany. Although there are fewer options in terms of flowers and extracts in the UK, there is a range of vape cartridges, produced from a variety of producers, including Curaleaf, Aurora®, Somaí and Noidecs. Additionally, Curaleaf has a selection of edible pastille gums on the market.
Upcoming: Prohibition Partners, The European Cannabis Report: 10th Edition – Pre-Order Now
Although there are considerably fewer medical cannabis flower products in the UK market, compared to Germany, the range of prices remains similar, with prices ranging from £3 – £14 per gram (€4 – €17 per gram). The most common price of medical cannabis flower is £8 – £9 per gram (€9.5 – €10.7 per gram), which is slightly higher than that of Germany.
Even though there are fewer economic choices of medical flowers in the UK compared to Germany, on average, prices are fairly homogenous across both markets. Highlighting the fact that both countries are facing higher levels of competition, leading to an increase in competitive pricing.
Additionally, prices remain similar due to the nature of the integrated European medical cannabis supply chain, where importers and suppliers acquire product from identical primary sources.
For more information on the state of the UK, visit Cannabis Europa 2025, where experts will discuss: A Sleeping Giant? A Deep Dive into the Potential of the UK Market on the 25th June 2025
The post UK vs Germany – Medical Cannabis Products & Prices appeared first on Business of Cannabis.
Continue reading...
In the early years of the European medical cannabis market (2017-2020), medical cannabis products in Europe predominantly stemmed from the Netherlands through products provided by Bedrocan; however, in recent years, Canada has emerged as the leading supplier to European markets.
However, as more European markets expand their medical cannabis frameworks, demand is growing rapidly for an increased variety and volume of products sourced through global and domestic supply chains. As these supply chains develop, product availability has expanded, and European patients now have unprecedented levels of choice.
The extent to which individual markets are able to offer a variety of products, price points, and formats is driven by a multitude of factors. These include the specific classification of medical cannabis, the product authorisation process, the number of patients/demand, regulations on imports, patient access and the level of competition.
The surge of medical cannabis product availability in Europe is most prominently seen in the German and UK markets. Both of these markets can be defined as free markets within the European medical cannabis industry due to their relatively low barriers of entry for companies and high patient demand.
Upcoming: Prohibition Partners, The European Cannabis Report: 10th Edition – Pre-Order Now
When assessing the number of products available to patients in the UK and Germany, it is clear that German patients have a larger selection of medical cannabis products, totalling 1,104 products, compared to the UK, totalling 399 medical cannabis products.
However, in terms of product format variety, the UK patients have more choices, as edibles and a broader range of vape products are available. The disparity between the two countries in terms of the number of products and product format variety is driven by several factors, including the patient size, the level of competition and the classification of medical cannabis.
Germany
Germany is by far the largest medical cannabis market in Europe in terms of patient size as well as product availability. In 2024 alone, the country imported over 72 tonnes of medical cannabis, which was fueled by 4th quarter imports following the implementation of the CanG and MedCanG.
The newly established cannabis framework in the country removed cannabis from Germany’s list of narcotics, as well as eased the trade, dispensation and prescribing of medical cannabis. This sparked a significant rise in private-pay patients, and thus the demand for imported products.
Although there is an extensive variety of flowers and extracts available on the German market, there are no edibles and only one vape product available. This is due to the fact that medical cannabis in Germany is sold as a magistral product and not as a prepackaged finished good; thus, the last production step, checking product quality and dose packaging, occurs in the pharmacies.
However, some pharmacies provide services such as creating capsules and formulations from extracts. Additionally, the one vape product on the market is assembled by the pharmacy itself.
Upcoming: Prohibition Partners, The European Cannabis Report: 10th Edition – Pre-Order Now
Due to the high level of competition and the wide range of medical cannabis flowers available in Germany, there is a large spread in average prices, ranging from roughly €4 – €17 per gram. The prices for medical cannabis flower have seen a significant fall throughout the years, as back in 2018 the average price was roughly €20 – €24 per gram; however, following the rise of patients, the adoption of the MedCanG and increased competition between suppliers, the most common price of medical cannabis flower is around €8 – €9 per gram.
It must also be noted that, as there is a considerable number of low-cost options available on the medical cannabis market, patients who historically purchased cannabis illicitly for their treatment no longer need to do so, as prices are lower than those found on the illicit market.
For more information on Germany’s medical cannabis prices, visit BofC X Mary Jane 2025, where experts will discuss Germany’s adult-use market on the 19th June 2025.
UK
Compared to Germany, the UK’s medical cannabis market is significantly smaller due to its stringent import and prescription requirements and the fact that the market is focused entirely on private-pay patients.
Medical cannabis in the UK is classified as an unlicensed special medicine; thus, importers are bound to strict licence requirements to import specials, only doctors with an FP10 controlled prescription pad on the GMC Specialist Register are allowed to prescribe medical cannabis and before each initial prescription a multidisciplinary peer group must discuss to decide if medical cannabis treatment is suitable for the patient.
In the UK, medical cannabis is sold as a finished product in pharmacies, thus, there is a larger variety in formats in the UK compared to Germany. Although there are fewer options in terms of flowers and extracts in the UK, there is a range of vape cartridges, produced from a variety of producers, including Curaleaf, Aurora®, Somaí and Noidecs. Additionally, Curaleaf has a selection of edible pastille gums on the market.
Upcoming: Prohibition Partners, The European Cannabis Report: 10th Edition – Pre-Order Now
Although there are considerably fewer medical cannabis flower products in the UK market, compared to Germany, the range of prices remains similar, with prices ranging from £3 – £14 per gram (€4 – €17 per gram). The most common price of medical cannabis flower is £8 – £9 per gram (€9.5 – €10.7 per gram), which is slightly higher than that of Germany.
Even though there are fewer economic choices of medical flowers in the UK compared to Germany, on average, prices are fairly homogenous across both markets. Highlighting the fact that both countries are facing higher levels of competition, leading to an increase in competitive pricing.
Additionally, prices remain similar due to the nature of the integrated European medical cannabis supply chain, where importers and suppliers acquire product from identical primary sources.
For more information on the state of the UK, visit Cannabis Europa 2025, where experts will discuss: A Sleeping Giant? A Deep Dive into the Potential of the UK Market on the 25th June 2025
The post UK vs Germany – Medical Cannabis Products & Prices appeared first on Business of Cannabis.
Continue reading...
